As of 2025-07-01, the EV/EBITDA ratio of Esperion Therapeutics Inc (ESPR) is -9.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ESPR's latest enterprise value is 373.47 mil USD. ESPR's TTM EBITDA according to its financial statements is -39.86 mil USD. Dividing these 2 quantities gives us the above ESPR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.9x - 13.6x | 10.9x |
| Forward P/E multiples | 14.0x - 25.8x | 19.6x |
| Fair Price | (2.70) - (0.64) | (1.90) |
| Upside | -374.0% - -164.8% | -292.6% |
| Date | EV/EBITDA |
| 2025-06-27 | -9.42 |
| 2025-06-26 | -9.55 |
| 2025-06-25 | -9.50 |
| 2025-06-24 | -9.80 |
| 2025-06-23 | -9.65 |
| 2025-06-20 | -9.80 |
| 2025-06-18 | -9.94 |
| 2025-06-17 | -9.90 |
| 2025-06-16 | -10.29 |
| 2025-06-13 | -10.29 |
| 2025-06-12 | -10.44 |
| 2025-06-11 | -10.49 |
| 2025-06-10 | -10.54 |
| 2025-06-09 | -10.44 |
| 2025-06-06 | -10.54 |
| 2025-06-05 | -10.24 |
| 2025-06-04 | -10.04 |
| 2025-06-03 | -9.70 |
| 2025-06-02 | -9.04 |
| 2025-05-30 | -8.70 |
| 2025-05-29 | -8.80 |
| 2025-05-28 | -8.63 |
| 2025-05-27 | -8.55 |
| 2025-05-23 | -8.40 |
| 2025-05-22 | -8.47 |
| 2025-05-21 | -8.72 |
| 2025-05-20 | -8.99 |
| 2025-05-19 | -8.77 |
| 2025-05-16 | -8.46 |
| 2025-05-15 | -8.34 |
| 2025-05-14 | -8.11 |
| 2025-05-13 | -8.36 |
| 2025-05-12 | -8.45 |
| 2025-05-09 | -8.44 |
| 2025-05-08 | -8.91 |
| 2025-05-07 | -8.81 |
| 2025-05-06 | -9.33 |
| 2025-05-05 | -9.70 |
| 2025-05-02 | -9.90 |
| 2025-05-01 | -9.37 |
| 2025-04-30 | -9.44 |
| 2025-04-29 | -9.25 |
| 2025-04-28 | -8.99 |
| 2025-04-25 | -9.05 |
| 2025-04-24 | -8.86 |
| 2025-04-23 | -9.20 |
| 2025-04-22 | -9.10 |
| 2025-04-21 | -8.71 |
| 2025-04-17 | -9.20 |
| 2025-04-16 | -9.27 |